Incyte's Oncology Strategy: Putting Its Eggs In Many Mechanistic Baskets

The financial springboard supplied by the successful JAK inhibitor Jakafi is allowing Incyte Corp. to tackle many new mechanisms all at once, including a second-generation PI3 kinase inhibitor and some of the hottest targets in immuno-oncology today – OX40 and GITR agonists – and rebound from some R&D disappointments.

The company showcased its full pipeline at the American Association for Cancer Research annual meeting in April and is planning on data releases in the second half of the year, perhaps at the European Society for Medical Oncology meeting in October, though during a May 9